Ozone therapy in colorectal cancer
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality, and metastatic progression, recurrence, chemoresistance, and treatment-related toxicity continue to limit outcomes. Medical ozone has attracted interest as a potential adjunct because, after reacting with biological fluids, it generates short-lived redox mediators such as hydrogen peroxide and lipid oxidation products that may influence NRF2/Keap1, NF-κB, HIF-1α, mitochondrial apoptosis, cytokine signaling, and the tumor microenvironment. However, current CRC-specific evidence is limited and heterogeneous. Experimental studies using CRC cell lines and animal models suggest possible effects on apoptosis, oxidative stress, inflammatory modulation, hypoxia-related pathways, and chemosensitivity, but these findings remain preclinical and are not sufficient to establish antitumor efficacy. Clinical evidence in CRC patients is scarce and mainly relates to supportive care, including radiation-induced rectal injury, chronic treatment-related symptoms, and chemotherapy-induced peripheral neuropathy, rather than tumor response or survival. Importantly, ozone biology is context dependent: activation of adaptive antioxidant responses may protect normal tissues but could also enhance tumor cell stress tolerance under certain conditions. Route-specific safety is also critical, as inhaled ozone is toxic, whereas non-inhalational approaches require standardized dosing and monitoring. Overall, ozone therapy should be considered an investigational adjunct in CRC, with future studies requiring rigorous trial design, biomarker stratification, standardized administration protocols, and clear separation of anticancer endpoints from symptom-control outcomes.
Related
- Re-Evaluating Multi-Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Combined Therapy in Colorectal Cancer: A Preclinical Study
- 270 AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
- Sequential colorectal cancer–based therapy including anti-angiogenics and 3rd-line trifluridine/tipiracil-bevacizumab for metastatic urachal adenocarcinoma: a case report
- Targeted photodynamic therapy for colorectal cancer using antibody-conjugated green-synthesised nanoparticles.
- Glutamine-Functionalized mRNA Lipid Nanoparticles Block HIF-1α-Dependent Glycolytic Adaptation to Sensitize Azelaic Acid Therapy in Colorectal Cancer
BibTeX
@article{li2026ozone,
title = {{Ozone therapy in colorectal cancer}},
author = {Yanchu Li and Rong Pu and Sen Yang and Hongxiu Chen and Xiaoxia Zhang},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1925327},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1925327},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ozone therapy in colorectal cancer
AU - Yanchu Li
AU - Rong Pu
AU - Sen Yang
AU - Hongxiu Chen
AU - Xiaoxia Zhang
PY - 2026
DA - 2026/10/30
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1925327
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1925327
AB - Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality, and metastatic progression, recurrence, chemoresistance, and treatment-related toxicity continue to limit outcomes. Medical ozone has attracted interest as a potential adjunct because, after reacting with biological fluids, it generates short-lived redox mediators such as hydrogen peroxide and lipid oxidation products that may influence NRF2/Keap1, NF-κB, HIF-1α, mitochondrial apoptosis, cytokine signaling, and the tumor microenvironment. However, current CRC-specific evidence is limited and heterogeneous. Experimental studies using CRC cell lines and animal models suggest possible effects on apoptosis, oxidative stress, inflammatory modulation, hypoxia-related pathways, and chemosensitivity, but these findings remain preclinical and are not sufficient to establish antitumor efficacy. Clinical evidence in CRC patients is scarce and mainly relates to supportive care, including radiation-induced rectal injury, chronic treatment-related symptoms, and chemotherapy-induced peripheral neuropathy, rather than tumor response or survival. Importantly, ozone biology is context dependent: activation of adaptive antioxidant responses may protect normal tissues but could also enhance tumor cell stress tolerance under certain conditions. Route-specific safety is also critical, as inhaled ozone is toxic, whereas non-inhalational approaches require standardized dosing and monitoring. Overall, ozone therapy should be considered an investigational adjunct in CRC, with future studies requiring rigorous trial design, biomarker stratification, standardized administration protocols, and clear separation of anticancer endpoints from symptom-control outcomes.
SN - 2234-943X
ER -